|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Johnson & Johnson (JNJ) Cuts 130 Jobs After Alzheimer Drug Fails
10/24/2012 7:58:33 AM
Johnson & Johnson | Jobs at Johnson & Johnson
This was expected, yes? Two months after reporting that a pair of clinical trials testing an Alzheimer’s compound failed to meet primary endpoints, Johnson & Johnson is eliminating about 130 positions, mostly from its Janssen Alzheimer Immunotherapy office in South San Francisco, California, according to a state notice. In an e-mail, a spokeswoman confirms that the “restructuring” and job cuts are due to the “negative clinical trial results announced in August of the bapineuzumab Phase III studies and the decision to discontinue development of bapineuzumab in mild-to-moderate Alzheimer’s disease.” The state notice lists 119 jobs to be eliminated from that office. At the moment, the unit employs about 200 people and also has a facility in Dublin, Ireland. The job cuts are hardly unexpected in light of the decision to halt clinical work, except for follow-up evaluations and final data analyses. In fact, preliminary results reported in 2008 suggested little room for optimism (see this), although many patients and investors held out hope that the compound would offer a pleasant surprise, despite the odds.
|
|
|
|
|
|
|
|
|
|
|